epothilone b

DRUG7 trials

Sponsors

Novartis Pharmaceuticals, David Peereboom, MD

Conditions

Breast CancerBreast NeoplasmsColonic NeoplasmsColorectal NeoplasmsFallopian Tube NeoplasmsKidney NeoplasmsMelanomaMetastatic Cancer

Phase 2

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

CompletedNCT00035100

Novartis PharmaceuticalsFallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Start: 2001-09-30Updated: 2012-04-16

EPO906 Therapy in Patients With Advanced Kidney Cancer

CompletedNCT00035243

Novartis PharmaceuticalsKidney Neoplasms

Start: 2002-04-30Updated: 2012-04-17

EPO906 Therapy in Patients With Prostate Cancer

CompletedNCT00035113

Novartis PharmaceuticalsProstatic Neoplasms

Start: 2002-01-31End: 2004-01-31Updated: 2017-02-09

EPO906 Therapy in Patients With Advanced Breast Cancer

CompletedNCT00035126

Novartis PharmaceuticalsBreast Neoplasms

Start: 2002-01-31End: 2003-11-30Updated: 2017-02-08

EPO906 Therapy in Patients With Advanced Melanoma

CompletedNCT00035165

Novartis PharmaceuticalsMelanoma

Start: 2002-03-31Updated: 2012-04-25

EPO906 Therapy in Patients With Advanced Colorectal Cancer

CompletedNCT00035087

Novartis PharmaceuticalsColonic Neoplasms, Colorectal Neoplasms

Start: 2002-05-31End: 2003-03-31Updated: 2013-12-04

Epothilone B in Treating Patients With CNS Metastases From Breast Cancer

CompletedNCT00450866

David Peereboom, MDBreast Cancer, Metastatic Cancer

Start: 2007-01-31End: 2012-05-31Updated: 2014-02-28